The ECHELON-2 trial: Results of a randomized, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas Meeting Abstract
| Authors: | Horwitz, S. M.; O'Connor, O. A.; Pro, B.; Illidge, T. M.; Fanale, M. A.; Advani, R. H.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; Kim, W. S.; Feldman, T. A.; Lennard, A.; Belada, D.; Illés, A.; Tobinai, K.; Tsukasaki, K.; Yeh, S. P.; Shustov, A. R.; Hüttmann, A.; Savage, K. J.; Yuen, S.; Zinzani, P. L.; Hua, Z.; Little, M.; Rao, S.; Woolery, J.; Manley, T.; Trümper, L. |
| Abstract Title: | The ECHELON-2 trial: Results of a randomized, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837603027 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-110563 |
| Notes: | Meeting Abstract: 997 -- Source: Wos |
